Patents Examined by Marcos L Sznaidman
  • Pharmaceutical composition containing rifaximin alpha and delta
    Patent number: 10576065
    Abstract: The present invention relates to a pharmaceutical composition containing rifaximin in the form of two different polymorphs as well as a method of preparing the same.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: March 3, 2020
    Assignee: Sandoz AG
    Inventor: Johannes Raneburger
  • Preparation and anti-HSV-1 application of quinolinone derivatives
    Patent number: 10568877
    Abstract: Provided herein are quinolinone derivatives and their uses as antiviral drugs, for example, for treatment of HSV-1 infection. Also provided herein are pharmaceutically acceptable compositions comprising the quinolinone derivatives and the uses of the composition in the treatment of diseases caused by HSV-1 virus.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: February 25, 2020
    Assignee: OCEAN UNIVERSITY OF CHINA
    Inventors: Changlun Shao, Changyun Wang, Rufang Xu, Feifei Guan, Meiyan Wei
  • Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines
    Patent number: 10564169
    Abstract: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: February 18, 2020
    Assignee: Colgate-Palmolive Company
    Inventor: Nolan Zebulon Frantz
  • Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
    Patent number: 10556878
    Abstract: A compound useful as a Sirt2 or Sirt5 inhibitor having the formula (1) wherein: R1 is a hydrocarbon group having at least two carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group is optionally endcapped by a neutral or anionic oxygen-containing group; R2a, R2b, and R2c are independently selected from hydrogen atom and hydrocarbon groups; X0, X1, X2, and X3 are independently selected from —(CH2)n—, —NR5—, —O—, —S—, and a bond, wherein n represents 1, 2, or 3, provided that at least one of X0-X3 is —(CH2)n—; and R3 and R4 are independently selected from the group consisting of hydrogen atom, hydrocarbon groups, biological groups, and protecting groups. Also described are pharmaceutical compositions of the inhibiting compounds, and methods of treatment by administration of the inhibiting compounds.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: February 11, 2020
    Assignee: CORNELL UNIVERSITY
    Inventor: Hening Lin
  • Bile acid recycling inhibitors for treatment of obesity and diabetes
    Patent number: 10555950
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 11, 2020
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Amino acid derivatives and absorbable polymers therefrom
    Patent number: 10550072
    Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 4, 2020
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S Bezwada
  • Inhibitors of protein kinases
    Patent number: 10533001
    Abstract: The present invention is directed to topical pharmaceutical compositions of Formula (If) or pharmaceutically acceptable salt thereof, which act as inhibitors of syk and/or JAK kinase activity. The described topical pharmaceutical compositions are useful in preventing or treating a number of conditions mediated at least in part by syk and/or JAK kinase activity.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 14, 2020
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
  • Histone demethylase inhibitors
    Patent number: 10526327
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 7, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Compositions for use in treating glioblastoma
    Patent number: 10512626
    Abstract: The present disclosure provides methods of treating glioblastoma multiform (GBM) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: December 24, 2019
    Assignee: PELOTON THERAPEAUTICS, INC.
    Inventor: John A. Josey
  • Method for treating cancer using a selenourea-coordinated gold(I)-carbene complex
    Patent number: 10507213
    Abstract: Gold(I)-carbene complexes having a selenium donor ligand with anti-cancer activity and a method of treating cancer. Methods of treating cancer comprising administering the complexes are also provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 17, 2019
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Adam A. A. Sulaiman, Mohammad Altaf, Anvarhusein A. Isab
  • Apoptosis signal-regulating kinase inhibitor
    Patent number: 10508100
    Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 17, 2019
    Assignee: Gilead Sciences, Inc.
    Inventor: Gregory Notte
  • Compositions and methods for treating bone diseases
    Patent number: 10500203
    Abstract: Certain aspects of the present invention generally relate to compositions and methods for treating a bone disease, for example a genetic bone disease. In one embodiment the bone disease is fibular hemimelia, proximal femoral focal deficiency, tarsal coalition or humeroradial synostosis.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: December 10, 2019
    Assignee: Rush University Medical Center
    Inventors: Di Chen, Rong Xie
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10485778
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 26, 2019
    Assignee: lo Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Amino pyrimidine derivatives
    Patent number: 10457647
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 29, 2019
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Use of butylidenephthalide
    Patent number: 10441566
    Abstract: Disclosed is the use of an active ingredient in the manufacture of a medicament, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt of butylidenephthalide, and combinations thereof, and wherein the medicament is used for the prevention and/or treatment of oral submucous fibrosis (OSF) and may be used in the form of an injection lozenge, oral solution, or smearing preparation.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: October 15, 2019
    Assignee: EVERFRONT BIOTECH INC.
    Inventors: Horng-Jyh Harn, Shinn-Zong Lin
  • Compounds for kinase modulation, and indications therefor
    Patent number: 10421761
    Abstract: Compounds active on protein kinases and methods for regulating protein kinase pathways are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 24, 2019
    Assignee: Plexxikon Inc.
    Inventors: Chao Zhang, Klaus-Peter Hirth, Prabha N. Ibrahim, Marika Nespi, Songyuan Shi, Wayne Spevak, Gaston G. Habets, Elizabeth A. Burton
  • Organomodified carbosiloxane monomers containing compositions and uses thereof
    Patent number: 10391179
    Abstract: There is provided novel mono-acrylate functionalized siloxane monomer containing carbosiloxane linkage for improved hydrolysis resistance. This invention also provides copolymers produced using these monomers and their use in various applications.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: August 27, 2019
    Assignee: Momentive Performance Materials Inc.
    Inventors: Anubhav Saxena, Umpathy Senthilkumar, Kenrick M. Lewis
  • Ocular iontophoretic delivery of dexamethasone and formulations thereof
    Patent number: 10376463
    Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: August 13, 2019
    Assignee: Eyegate Pharmaceuticals, Inc.
    Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
  • Treatment of inflammatory diseases with inhibitors of C5a activity
    Patent number: 10376595
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 13, 2019
    Assignee: InflaRx GmbH
    Inventors: Renfeng Guo, Niels C. Riedemann
  • Crystal form of JAK inhibitor and preparation method thereof
    Patent number: 10377757
    Abstract: The present disclosure relates to novel crystalline forms of JAK inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis. The novel crystalline forms in the present disclosure have good stability and remarkable purification effect in process, moreover, its solubility and hygroscopicity meet the requirements for medical use. The preparation method of novel crystalline forms is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: August 13, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Nan Xia, Xiaoyu Zhang